Interleukin-9 promotes EMT-mediated PM2.5-induced pulmonary fibrosis by activating the STAT3 pathway

Yuxuan Li1, Yi Zhong1, Chenwen Li1,2

  • 1Environmental Health Effects and Risk Assessment Key Laboratory of Luzhou, School of Public Health, Southwest Medical University, Luzhou, 646000, China.

Archives of Toxicology
|September 11, 2024
PubMed

Insights

Fine particulate matter (PM2.5) exposure causes pulmonary fibrosis by activating the IL-9/STAT3 pathway, promoting epithelial-mesenchymal transition (EMT). This study reveals PM2.5

Area of Science:

  • Environmental Health
  • Pulmonary Medicine
  • Molecular Biology

Background:

  • Particulate matter (PM2.5) is a major air pollutant linked to respiratory diseases.
  • Pulmonary fibrosis (PF) is a chronic lung disease characterized by progressive scarring.
  • Epithelial-mesenchymal transition (EMT) plays a crucial role in the pathogenesis of PF.

Purpose of the Study:

  • To investigate the role of PM2.5 in promoting EMT in PF development.
  • To elucidate the molecular mechanisms involving the IL-9/STAT3/Snail/TWIST1 signaling pathway in PM2.5-induced PF.

Main Methods:

  • Male Sprague-Dawley rats were exposed to varying doses of PM2.5 via intratracheal instillation for 16 weeks.
  • Pulmonary epithelial cells were treated with PM2.5 and specific pathway inhibitors.
  • Serum, bronchoalveolar lavage fluid (BALF), and lung tissues were analyzed for protein and gene expression.

Main Results:

  • PM2.5 exposure led to significant lung tissue damage and PF development in rats.
  • Elevated levels of IL-9, IL-9R, p-STAT3, Snail, TWIST1, Vimentin, COL-I, and α-SMA were observed in PM2.5-exposed groups.
  • Decreased E-Cadherin levels and increased EMT markers were noted in PM2.5-treated cells, which were reversed by STAT3 inhibition or IL-9 neutralization.

Conclusions:

  • PM2.5 induces pulmonary fibrosis by promoting IL-9 expression.
  • The IL-9/STAT3 signaling pathway is critical for PM2.5-mediated EMT and PF.
  • Targeting this pathway may offer therapeutic strategies for PM2.5-related lung diseases.